CTIX in discussions with MD Anderson Cancer Institute?
8-K Filing yesterday:
On December 21, 2012 the Company signed a Confidential Disclosure Agreement with one of the world’s most prominent cancer centers, located in the Southwest United States, who contacted Cellceutix indicating that they are interested in conducting studies of Kevetrin at their cancer center. Furthermore, they informed us that they are prepared to fund the costs of these studies. Although the Company believes that a full-fledged collaboration agreement will be signed in the very near term, as of the date of this report, such an agreement has not yet been executed. There is therefore no assurance that such agreement will be executed.